Novartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthma

  • Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) was superior to once-daily IND/MF (QMF149) in improving the lung function of patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment1
     
  • In secondary analyses, improvements in lung function were observed with high- and medium-dose IND/GLY/MF compared to high-dose Sal/Flu1
     
  • In other secondary analyses, clinically meaningful reductions in moderate-to-severe (36%) and severe (42%) asthma exacerbation rates were observed with high- …
/by